PIP Search Page

Displaying 21 - 40 of 122

PIPS Search Results
PIP Number	Active Substance Sort descending	Conditions / Indications	Invented Name	Therapeutic area	Decision Type	Compliance Check	Date Published
MHRA-100276-PIP01-21-M03 (update)	BRODALUMAB	Treatment of psoriasis	Kyntheum Kyntheum Lumicef Siliq Kyntheum Kyntheum Kyntheum	Dermatology	W: decision granting a waiver in all age groups for the listed condition(s).	No	30/01/2024
MHRA-101270-PIP01-23	SEMAGLUTIDE	Prevention of cardiovascular events in patients with atherosclerosis	Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy Wegovy	Endocrinology-Gynaecology-Fertility-metabolism	W: decision granting a waiver in all age groups for the listed condition(s).	No	30/04/2024
MHRA-100368-PIP01-21	aumolertinib	Treatment of lung cancer	Ameile	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	17/05/2022
MHRA-100206-PIP01-21	EMPAGLIFLOZIN	Treatment of ischaemic heart disease	Jardiance Jardiance	Endocrinology-Gynaecology-Fertility-metabolism	W: decision granting a waiver in all age groups for the listed condition(s).	No	19/05/2022
MHRA-100135-PIP01-21	anti-CD40L humanized monoclonal antibody (SAR441344)	Treatment of Sjogren's Syndrome		Immunology -Rheumatology-Transplantation	W: decision granting a waiver in all age groups for the listed condition(s).	No	17/05/2022
MHRA-100204-PIP01-21	verdiperstat	Treatment of Amyotrophic lateral sclerosis	Dazluma	Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No	19/05/2022
MHRA-100194-PIP01-21	sivopixant	Treatment of unexplained or refractory chronic cough		Pneumology - Allergology	W: decision granting a waiver in all age groups for the listed condition(s).	No	19/05/2022
MHRA-100309-PIP01-21	gantenerumab	Prevention of Alzheimer's disease	Not available at present	Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No	19/05/2022
MHRA-100301-PIP01-21	Anti-neonatal Fc receptor human monoclonal antibody(Nipocalimab )	Treatment of chronic inflammatory demyelinating polyradiculoneuropathy		Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No	19/05/2022
MHRA-100396-PIP01-21	sugemalimab	Treatment of non-small cell lung cancer (NSCLC)		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	29/07/2022
MHRA-100316-PIP01-21	latozinemab	Treatment of clinically symptomatic or pre-symptomatic frontotemporal dementia (FTD)		Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No	29/07/2022
MHRA-100806-PIP01-22	ALPELISIB	Treatment of ovarian cancer (excluding rhabdomyosarcoma and germ cell tumours) Treatment of Fallopian cancer (excluding rhabdomyosarcoma and germ cell tumours) Treatment of Peritoneal cancer (excluding blastomas and sarcomas).	Piqray Piqray	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	24/08/2023
MHRA-100122-PIP01-21	olpasiran	Prevention of cardiovascular events		Cardiovascular Diseases	W: decision granting a waiver in all age groups for the listed condition(s).	No	29/07/2022
MHRA-100190-PIP01-21	Ordesekimab	Treatment of coeliac disease		Gastroenterology-Hepatology Immunology -Rheumatology-Transplantation	W: decision granting a waiver in all age groups for the listed condition(s).	No	29/07/2022
MHRA-100295-PIP01-21	Adalimumab conjugated with (4S)-4-[2-(2-bromoacetamido)acetamido]-5-{3-[(4-{(4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-4a,6a-dimethyl-2-oxo-6b-[(phosphonooxy)acetyl]-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H,8H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8-yl}phenyl)methyl] anilino}-5-oxopentanoic acid; (ABBV-154).	Treatment of polymyalgia rheumatica		Immunology -Rheumatology-Transplantation	W: decision granting a waiver in all age groups for the listed condition(s).	No	27/09/2022
MHRA-100374-PIP01-21	Adeno-associated virus serotype 1 vector containing the human progranulin GRN gene	Treatment of frontotemporal dementia		Neurology	W: decision granting a waiver in all age groups for the listed condition(s).	No	27/09/2022
MHRA-100454-PIP01-22	adagrasib	Treatment of all solid and haematological malignancies		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	27/09/2022
MHRA-100136-PIP01-21	PEMBROLIZUMAB quavonlimab	All conditions of malignant neoplasms (except haematopoietic, lymphoid tissue and melanoma).		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	27/09/2022
MHRA-100125-PIP01-21	PEMBROLIZUMAB vibostolimab	Malignant neoplasms (except CNS, haematopoietic, lymphoid tissue melanoma) Malignant CNS neoplasms		Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	27/09/2022
MHRA-100874-PIP01-23	PEMBROLIZUMAB	Treatment of all conditions included in the category of malignant neoplasms (except nervous system, haematopoietic and lymphoid tissue) Treatment of Hodgkin lymphoma	Keytruda	Oncology	W: decision granting a waiver in all age groups for the listed condition(s).	No	19/12/2023

Download XLSX

Search Filters: